A comprehensive meta-analysis of 36 randomised controlled trials reveals GLP-1 receptor agonists are associated with significant lean body mass loss — here’s what it means for the $100B+ peptide drug class.
Vedana Therapeutics launches with $46M Series A to develop anti-PACAP antibody drugs for migraine prevention, joining an intensifying race around a neuropeptide target that could address the 50%+ of patients who fail CGRP therapies.
Sciwind Biosciences’ cAMP-biased GLP-1 analogue ecnoglutide shows no clinically significant drug-drug interactions with rosuvastatin or digoxin in a Phase 1 study, while delivering 11.2% weight loss over 14 weeks. The findings support the peptide’s march toward regulatory filing after two positive Phase 3 trials published in The Lancet.
The European Commission has approved CinnaGen’s Zandoriah, the first teriparatide biosimilar for osteoporosis. What does this regulatory milestone mean for the broader peptide therapeutics and biosimilar manufacturing landscape?
Oral peptides will replace injectables for some classes — GLP-1s are leading — but not most. The economics of 1% bioavailability mean oral delivery only works for large-market, high-price peptides. For many, a once-weekly injection is more convenient than a daily fasting pill.
FDA approved 28 peptide drugs from 2020 to mid-2026. Linear peptides dominate (61%), but macrocycle INDs surged 140% in 2 years. The 36% CRL rate for peptide NDAs is a warning: CMC rehearsal is the cheapest insurance against a 12-month approval delay.
Peptide purification accounts for 30-50% of API cost and remains the manufacturing bottleneck no one discusses. This guide covers RP-HPLC, SMB, nanofiltration, and the emerging methods that could reshape purification economics.
CagriSema — Novo Nordisk’s semaglutide/cagrilintide combo — achieved 15.6% weight loss in Phase II with complementary GLP-1 and amylin pathway engagement. Phase III data expected H2 2026 will determine whether it can compete with tirzepatide’s 21.1%.
Peptide stability testing errors — from testing only at pH 7.4 to filing without forced degradation data — are the leading cause of peptide CMC Complete Response Letters. Experienced developers begin stability studies at lead optimization, not after formulation lock.
Eight companies are racing to launch biosimilar semaglutide, but $500M capital requirements and 40+ process patents will limit the field to 3-4 entrants. The first biosimilar is expected in 2028 at a 25-35% discount — not the 80-90% of small-molecule generics.
TIDES 2026: oral GLP-1/GIP dual agonists at 4.8% bioavailability, kilo-scale enzymatic macrocycle cyclization, FDA purity signals, first AI-designed peptide in the clinic, and India’s GMP peptide manufacturing debut.
Chinese CDMOs added 1.8 tons of annual SPPS capacity in 3 years, on track for 40% of global peptide API production by 2028. Capital costs are 60% lower than Europe, and FDA inspection records are clean. The risk is not quality — it is geopolitics.
